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Abstract 
Background: Vasopressors are commonly applied to restore and maintain blood pressure in patients with sepsis. We 
aimed to evaluate the current practice and therapeutic goals regarding vasopressor use in septic shock as a basis for 
future studies and to provide some recommendations on their use.
Methods: From November 2016 to April 2017, an anonymous web‑based survey on the use of vasoactive drugs was 
accessible to members of the European Society of Intensive Care Medicine (ESICM). A total of 17 questions focused 
on the profile of respondents, triggering factors, first choice agent, dosing, timing, targets, additional treatments, and 
effects of vasopressors. We investigated whether the answers complied with current guidelines. In addition, a group 
of 34 international ESICM experts was asked to formulate recommendations for the use of vasopressors based on 6 
questions with sub‑questions (total 14).
Results: A total of 839 physicians from 82 countries (65% main specialty/activity intensive care) responded. The 
main trigger for vasopressor use was an insufficient mean arterial pressure (MAP) response to initial fluid resuscitation 
(83%). The first‑line vasopressor was norepinephrine (97%), targeting predominantly a MAP > 60–65 mmHg (70%), 
with higher targets in patients with chronic arterial hypertension (79%). The experts agreed on 10 recommendations, 
9 of which were based on unanimous or strong (≥ 80%) agreement. They recommended not to delay vasopressor 
treatment until fluid resuscitation is completed but rather to start with norepinephrine early to achieve a target MAP 
of ≥ 65 mmHg.
Conclusion: Reported vasopressor use in septic shock is compliant with contemporary guidelines. Future studies 
should focus on individualized treatment targets including earlier use of vasopressors.
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Background
Circulatory shock affects about one-third of patients 
admitted to intensive care [1] and is associated with 
increased mortality rates [1–3]. Four pathophysiologi-
cal mechanisms of shock (i.e., distributive, hypovolemic, 
cardiogenic, and obstructive) have been distinguished [3, 
4], which can be present alone or in combination [5]. In 
patients requiring vasopressor therapy, the majority are 
diagnosed as having septic shock (62%), followed by car-
diogenic and hypovolemic shock (both 16%), and other 
types of distributive shock (4%) and obstructive shock 
(2%) [6]. In this work, we focused on septic shock, as the 
most common form of distributive shock.
The essential step in the management of patients with 
septic shock is to increase systemic and regional/micro-
circulatory flow. Increasing arterial blood pressure 
(ABP) with vasopressors when patients are hypoten-
sive is used to improve the input pressure driving organ 
perfusion. However, except for the choice of the first-
line agent (norepinephrine), there is no clear consensus 
regarding the use of vasopressors in septic shock. For 
instance, for life-threatening sepsis-induced hypoten-
sion, the 2012 Surviving Sepsis Campaign (SSC) guide-
lines recommended early initiation of norepinephrine in 
patients with low diastolic blood pressure (as marker of 
low arterial tone) [7]. However, the most recent 2016 SSC 
guidelines are less precise about the appropriate time to 
initiate norepinephrine [8] so the question about opti-
mal timing remains. The guidelines recommend a mean 
arterial pressure (MAP) of at least 65  mmHg should be 
used as an initial target value [8] and that vasopressors 
should be started immediately if patients remain hypo-
tensive during or after fluid resuscitation (strong recom-
mendation, moderate quality of evidence) [9]. Higher 
targets should be considered in patients with chronic 
arterial hypertension, although this remains controversial 
[2, 8, 10]. However, some data suggest that individualiza-
tion of the MAP target alone may not improve outcome 
[11], so other measures should be considered to increase 
systemic blood flow. Furthermore, it is still a matter of 
debate whether vasopressin or other agents should be 
added to norepinephrine in cases of refractory hypoten-
sion [12]. Vasopressin use may be associated with a lower 
risk of atrial fibrillation and mortality [13]. Finally, infor-
mation on vasopressor tolerance, side effects, and poten-
tial effects on cardiac function is scarce.
Therefore, hemodynamic management of early septic 
shock is a perpetual work in progress with unresolved 
questions and low quality of evidence [14], and further 
research on the optimal use of vasopressors is needed. 
Yet, to aid the design and interpretation of future stud-
ies, it is imperative to establish a knowledge base of what 
can be considered standard of care. We thus aimed to 
evaluate current practice, preferences, and therapeu-
tic goals on the use of vasopressor drugs in the treat-
ment of patients with septic shock. Furthermore, based 
on the answers, we identified areas of interest for which 
we approached international experts in the field for their 
opinions/recommendations.
Methods
A survey was developed by the Cardiovascular Dynam-
ics Section of the European Society of Intensive Care 
Medicine (ESICM). The survey consisted of 27 questions 
on the use of vasoactive drugs. This article focuses on 
17 questions related to the use of vasopressors in septic 
shock, defined as persistent hypotension despite fluid 
resuscitation [15–17]. These were organized into two 
main sections: (1) the profile of respondents and their 
centers (Table  1) and (2) triggering factors, first-line 
drug choice, dosing, timing, targets, additional treatment 
strategies, and effects of vasopressors (Table 2).
Survey development
The questionnaire was developed by TWLS and JLT. The 
Research Committee of the ESICM endorsed the sur-
vey. It was not pretested beforehand. Data were collected 
automatically using SurveyMonkey Inc. (www.surve 
ymonk ey.com). No personal information was collected, 
and no log-in was required to participate. Completion 
or internal consistency of items was enforced by display-
ing an alert before the questionnaire was submitted and 
by highlighting mandatory but unanswered questions. It 
was not possible to review and change the given answers 
after submission. The 17 questionnaire items related to 
this study are provided in Tables 1 and 2.
The survey was announced on the ESICM website and 
was open for participation between November 2016 and 
April 2017. Members of the Cardiovascular Dynam-
ics section of the ESICM were additionally encouraged 
to participate via an email linking to the survey sent to 
email addresses in ESICM’s membership database in 
November 2016 with two subsequent email reminders in 
February and March 2017. No incentives were offered for 
participation.
Survey reporting
The methodology and results of the questionnaire are 
reported according to the Checklist for Reporting Results 
of Internet E-Surveys (CHERRIES) statement [18]. Ethi-
cal approval was not requested as this was a voluntary 
survey, and no individual patient data were collected.
Experts’ recommendations
Based on the analysis of the results, three authors 
(TWLS, IVDH and JLT) identified areas of interest and 
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developed six questions, including sub-questions and 
approached a group of 34 experts who are active mem-
bers of the Cardiovascular Dynamics Section of the 
ESICM, and who all have published research as first or 
last author in an international peer-reviewed journal 
in articles identified by the PubMed subject headings 
“vasopressor.” These experts were asked to formulate 
recommendations for the optimal use of vasopressors. 
Definitions of degree of consensus and grades of recom-
mendations were based on the RAND algorithm (Fig. 1) 
[19]. Perfect consensus (all experts agreeing) and good 
consensus (≥ 80% agreement) were considered as strong 
grades of recommendation. Conditional recommenda-
tion was used when 70–80% of the experts agreed.
The questions posed to the experts are presented in 
Table  3. Sub-question 5e on the use of corticosteroids 
in refractory hypotension [20] was resent to the experts 
following the results of the ADRENAL [21] and APROC-
CHSS trials [22] to see whether these study results had 
changed their opinion.
Statistics
Data were evaluated as the total distribution of single 
answers and then divided according to the geographical 
area of respondents within Europe and outside Europe 
using descriptive statistics. Answers to the questionnaire 
items are reported as numbers (percentage). Contin-
gency tables and corresponding Chi-square statistics are 
reported to describe the pairwise associations between 
selected demographic variables (European vs. non-Euro-
pean ESICM member, high-income vs. lower-income 
countries, intensive care unit (ICU) experience more vs. 
less than 5 years full time, intensive care (IC) as primary 
specialty vs. other specialties, and university hospital vs. 
non-university hospital) and the responses regarding 
vasopressor use. We used the World Bank definition of 
a “high-income country,” i.e., a per capita gross national 
income of $12,056 or more [23].
All descriptive and statistical analyses were performed 
in R (R studio version 1.1.453, running R version 3.5.0).
Results
A total of 839 physicians from 82 countries partici-
pated in the survey. A response rate could not be cal-
culated as the invitation to the survey was posted as 
a link on the ESICM open website. In addition, mem-
bers of the CD section of the ESICM (n = 10,780 at 
the time of the survey) received an email invitation to 
participate. From these addressees, 3111 (29%) opened 
this email (according to Mail Chimp). Baseline char-
acteristics of responders and their ICUs are presented 
in Table  1. Of the 839 participants, 546 (65%) were 
European (Fig.  2), 227 (27%) were from lower-income 
countries, and 353 (42%) were working in a university 
hospital. Four hundred and forty-five (53%) had more 
than 5  years of experience as an intensivist, and 545 
(65%) had Intensive Care as their main specialty or 
activity area. All ten survey questions and answers of 
the physicians on arterial blood pressure and vasopres-
sors are summarized in Table  2. Arterial blood pres-
sure was always measured invasively by 707 (84%) of 
Table 1 Baseline characteristics of survey respondents
Response rate
Total Europe Outside Europe
Valid respondents 839 (100%) 546 (65%) 293 (35%)
Main specialty area
 Intensive care 545 (65%) 313 (57%) 232 (79%)
 Anesthesiology 197 (23%) 164 (30%) 33 (11%)
 Internal medicine 53 (6%) 44 (8%) 9 (3%)
 Surgery 8 (1%) 3 (0.5%) 5 (2%)
 Other 36 (4%) 22 (4%) 14 (5%)
Experience as intensivist
 Full time > 5 years 445 (53%) 282 (52%) 163 (56%)
 Full time 2–5 years 98 (12%) 49 (9%) 49 (17%)
 Full time < 2 years 46 (5%) 26 (5%) 20 (7%)
 Part time intensivist 141 (17%) 116 (21%) 25 (9%)
 Not specialized (yet) 108 (13%) 73 (13%) 35 (12%)
Type of institution
 University hospital 353 (42%) 262 (48%) 91 (31%)
 Non‑university public 
hospital
183 (22%) 149 (27%) 34 (12%)
 University affiliated 
hospital
178 (21%) 100 (18%) 78 (27%)
 Private hospital 113 (13%) 31 (6%) 82 (28%)
 Other 12 (1%) 4 (1%) 8 (3%)
Type of ICU
 Mixed ICU 627 (75%) 408 (75%) 219 (75%)
 Surgical ICU 88 (10%) 68 (12%) 20 (7%)
 Medical ICU 83 (10%) 50 (9%) 33 (11%)
 Other 41 (5%) 20 (4%) 21 (7%)
Number of ICU beds
 ≤ 5 23 (3%) 16 (3%) 7 (2%)
 6–10 221 (26%) 176 (32%) 45 (15%)
 11–15 188 (22%) 135 (25%) 53 (18%)
 16–20 150 (18%) 89 (16%) 61 (21%)
 ≥ 20 257 (31%) 130 (24%) 127 (43%)
Number of patients admitted per year
 < 500 188 (22%) 135 (25%) 53 (18%)
 500–1000 291 (35%) 193 (35%) 98 (33%)
 1001–1500 178 (21%) 115 (21%) 63 (22%)
 1501–2000 92 (11%) 58 (11%) 34 (12%)
 > 2000 90 (11%) 45 (8%) 45 (15%)
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Table 2 Survey questions and answers on vasopressor use 
in septic shock
Respondents
No (%)
How do you measure arterial blood pressure in septic 
shock?
 Always invasively and continuously via an arterial line 707 (84%)
 Invasively only in case of severe shock 97 (12%)
 Mostly non‑invasively and discontinuously (arm cuff ) 32 (4%)
 Mostly non‑invasively but continuously using applana‑
tion tonometry
2 (0.3%)
 Mostly non‑invasively but continuously using finger 
cuff
1 (0.1%)
What is your main triggering factor(s) for initiating a 
vasopressor in septic shock?
 A low diastolic blood pressure whatever the correction 
of hypovolemia
29 (3%)
 Insufficient cardiac output response to the initial fluid 
resuscitation
56 (7%)
 Insufficient central venous oxygen saturation response 
to the initial fluid resuscitation
16 (2%)
 Insufficient mean arterial pressure response to the 
initial fluid resuscitation
700 (83%)
 Other 38 (5%)
What is your first line vasopressor in the treatment of 
hypotension?
 Adrenaline/epinephrine 4 (0.5%)
 Dopamine 17 (2%)
 Noradrenaline/norepinephrine 816 (97%)
 Vasopressin/terlipressin 2 (0.3%)
 Phenylephrine 0 (0%)
When do you use your vasopressor?
 I try to avoid any use of vasopressors and stick to 
volume therapy
15 (2%)
 I use a vasopressor early, before complete volume 
resuscitation (despite preload dependency)
104 (12%)
 I use a vasopressor only after assessment of preload 
dependency
371 (44%)
 I use a vasopressor only after completed treatment of 
preload dependency
228 (27%)
 I use a vasopressor regardless of preload dependency 121 (14%)
What is your main reason for increasing the dose of the 
vasopressor used?
 Diastolic arterial pressure target not reached 13 (2%)
 Mean arterial pressure target not reached 568 (68%)
 No arterial blood pressure response to the current dose 63 (8%)
 Signs of organ dysfunction despite reaching the arterial 
blood pressure target
173 (21%)
 Systolic arterial pressure target not reached 22 (3%)
What is your arterial blood pressure target for vasopres‑
sor therapy?
 A diastolic blood pressure > 40 mmHg 12 (1%)
 A mean arterial pressure > 60–65 mmHg 584 (70%)
 A mean arterial pressure > 70–75 mmHg 207 (25%)
Table 2 (continued)
Respondents
No (%)
 A mean arterial pressure > 80–85 mmHg 24 (3%)
 A systolic blood pressure > 100 mmHg 12 (1%)
Which patient’s factor(s) may encourage you to increase 
your arterial blood pressure target?
 Age 14 (2%)
 History of chronic hypertension 662 (79%)
 History of coronary artery disease 52 (6%)
 None of them 102 (12%)
 Value of central venous pressure 9 (1%)
When the patient does not respond to your current vaso‑
pressor therapy, what is your main reason for adding 
another vasopressor agent to the current therapy?
 A pre‑defined maximum dose of the 1st choice vaso‑
pressor has been reached
119 (14%)
 Although the pre‑defined maximum dose of the 1st 
choice vasopressor has not been reached, previous 
increases in the dose of this vasopressor were inef‑
fective
135 (16%)
 By adding a second vasopressor although the pre‑
defined maximum dose of the 1st choice vasopressor 
has not been reached, I want to limit/reduce the 
side‑effects of the first vasopressor
173 (21%)
 I suppose that the mechanism of action of the first 
vasopressor is exhausted (e.g., adrenoceptors down 
regulation) and want to use a second one with an 
independent mechanism of action
213 (25%)
 I want to use synergistic effects of two different mecha‑
nisms of action
199 (24%)
What is your main reason for reducing or stopping 
vasopressor therapy?
 Arterial blood pressure targets have been reached 463 (55%)
 I am concerned by potential side effects of current 
vasopressor therapy
39 (5%)
 Side effects of current vasopressor have occurred 15 (2%)
 The patient’s clinical situation is improving even if the 
arterial blood pressure target has not been reached
296 (35%)
 Vasopressor treatment is futile 26 (3%)
Which of the following statements fits best your opinion 
on norepinephrine use in the treatment of shock?
 Restoring mean arterial pressure with norepinephrine is 
usually associated with a decrease in systemic blood 
flow
69 (8%)
 Restoring mean arterial pressure with norepinephrine 
is usually associated with a deterioration of renal 
function
9 (1%)
 Restoring mean arterial pressure with norepinephrine 
is usually associated with a reduction in microcircula‑
tory blood flow and/or tissue oxygenation
201 (24%)
 Restoring mean arterial pressure with norepinephrine is 
usually associated with an increase in systemic blood 
flow
442 (53%)
 Restoring mean arterial pressure with norepinephrine is 
usually associated with no change in systemic blood 
flow
118 (14%)
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the participants. More non-European than European 
physicians (31% vs. 7.5%, p < 0.05), more respondents 
from lower-income countries than from high-income 
countries (37% vs. 8%, p < 0.001), and more IC special-
ists than non-intensivists (18% vs. 12%, p < 0.05) did not 
always measure ABP invasively. Norepinephrine was 
used by 816 (97%) respondents as the first-line vaso-
pressor in septic shock, while more respondents from 
lower-income countries preferred a different vasopres-
sor (6% vs. 1.5% from high-income countries, p < 0.001). 
Intensivists working in a university hospital were more 
likely to use another vasopressor than norepineph-
rine as their first-line treatment (4.5% vs. 1.4% of doc-
tors working in non-university hospitals, p < 0.05). An 
insufficient MAP response to initial fluid treatment was 
the main trigger to initiate vasopressor administration 
as reported by 700 (83%). Early use of a vasopressor 
(despite/regardless of preload dependency) was pre-
ferred by 225 (26%) responders. A blood pressure target 
of MAP > 60–65 mmHg or DAP > 40 mmHg was chosen 
by 596 (71%) of respondents, with more respondents 
working in a university hospital preferring this tar-
get (75% vs. 68% of doctors working in non-university 
Fig. 1 RAND algorithm. Method used to define the degree of consensus and grades of recommendations of the experts’ recommendations
Table 3 Questions to experts on vasopressor use
1. How should arterial blood pressure (ABP) be monitored in patients 
with septic shock?
2. What is the ideal time to start vasopressor therapy in treating septic 
shock?
 a. Should hypovolemia be completely corrected first?
 b. Which variable do you consider most helpful in deciding when to 
start vasopressor treatment?
3. Which vasopressor should be used as first choice?
 a. Are there situations or patient categories in which a certain vasopres‑
sor should be preferred?
4. What is your target? Which variable and which value?
5. Concerning refractory hypotension [20]
 a. What is your definition of refractory hypotension?
 b. Do you accept a lower MAP when it is not possible to achieve the 
target MAP with high‑dose vasopressors? In which situations?
 c. When should a second vasopressor agent be considered? Which one?
 d. Should it replace or be added to the first‑choice vasopressor?
 e. Should corticosteroids be used to reach the target?
6. What is your main reason for reducing or stopping vasopressor treat‑
ment?
Page 6 of 12Scheeren et al. Ann. Intensive Care            (2019) 9:20 
hospitals, p < 0.05). Six hundred and sixty-two (79%) 
participants modified their ABP target in patients with 
a history of chronic arterial hypertension. In addition, 
19% of IC specialists considered reasons other than 
chronic hypertension (mostly non-patient related fac-
tors) as a trigger to increase their ABP target versus 
26% of non-intensivists (p < 0.05). While the main rea-
son for increasing the vasopressor dose was failure to 
reach the targeted blood pressure (68%), some respond-
ents increased vasopressor doses for other reasons; e.g., 
signs of organ dysfunction despite reaching the MAP 
target. European-based intensivists and IC specialists 
more frequently chose to increase vasopressor dosages 
beyond reaching the target blood pressure (35% vs. 27% 
of non-Europeans, p < 0.05 and 37% vs. 30% of IC spe-
cialists, p < 0.05). There were no differences in any of 
the answers between experienced and less-experienced 
(< 5-year ICU experience) physicians.
The 34 experts agreed on 10 recommendations con-
cerning arterial blood pressure and use of vasopressors 
and corticosteroids, 9 of which were strong (see 
Table  4). In addition, they recommended not to delay 
vasopressor treatment until fluid resuscitation has 
been completed, but rather start with norepinephrine 
early to achieve a target MAP of ≥ 65  mmHg, and to 
accept a lower MAP if it is sufficient to correct signs of 
hypoperfusion.
Discussion
Norepinephrine was reported to be the first-line vaso-
pressor used to achieve MAP targets for almost all 
respondents to our online survey. Furthermore, a major-
ity of respondents and experts would target an initial 
MAP of 65 mmHg or higher. These findings are in con-
cordance with current guidelines for the management of 
sepsis and septic shock that recommend an initial target 
MAP of 65  mmHg and to titrate to individual require-
ments thereafter [8]. Notably, data from registries and 
major trials revealed that the average MAP in actual 
practice ranged between 75 and 80 mmHg. For example, 
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in the SEPSISPAM trial, MAP was 75 mmHg in the low 
blood pressure group, whereas the prescribed target 
range was 65–70 mmHg [24]. Similarly, in the OVATION 
trial, half of the MAP measurements were above the tar-
geted range [25]. This could suggest that healthcare pro-
fessionals in the ICU used the higher blood pressures as 
a “safety-cushion” to prevent dipping below the target or 
that the vasopressor doses were not lowered when MAP 
improved. Recent retrospective analysis from 110 US 
hospitals shows that risks for mortality, AKI, and myo-
cardial injury in septic patients progressively worsened at 
MAP thresholds lower than 85 mmHg [26].
Strikingly, the majority of respondents evaluate the 
effects of their initial resuscitation efforts based on their 
effects on blood pressure, whereas only 7% used cardiac 
output for this purpose. This is in line with previous stud-
ies [27, 28] but in contrast to the rational of fluid resusci-
tation which is to increase blood flow, i.e., cardiac output 
and oxygen delivery to ultimately improve tissue perfu-
sion and oxygenation.
A large majority of physicians stated they would raise 
their ABP targets when the patient had a history of 
chronic arterial hypertension; this is also in line with 
current recommendations of the European consensus 
conference [2]. This strategy is based on alterations in 
autoregulation of organ perfusion occurring in hyper-
tensive patients, although cerebral, hepatosplanchnic 
and renal autoregulation may be disturbed in the pres-
ence of severe systemic inflammation [29]. The SEPSIS-
PAM trial found that targeting a higher MAP in septic 
patients with chronic arterial hypertension led to less 
requirement for renal replacement therapy [24]. On the 
other hand, a multicenter pilot randomized controlled 
trial reported that in patients aged ≥ 75  years, a lower 
MAP target (60–65 mmHg) was associated with a lower 
hospital mortality (13% vs. 60%, p = 0.03), while this was 
not true for younger patients [25]. Importantly, only 25 
patients (8 deaths) were enrolled in the ≥ 75-year age-
group so these results need to be interpreted with cau-
tion. A recent individual patient data meta‐analysis from 
two major trials comparing higher versus lower MAP 
targets revealed that higher MAP targets may be associ-
ated with a higher mortality, particularly when patients 
had been treated with vasopressors for > 6 h before inclu-
sion [11]. Another cohort study on vasopressor use for 
severe arterial hypotension reported an average MAP 
of 75 mmHg and that ICU staff did not tailor vasopres-
sor therapy to individual patient characteristics such as 
underlying chronic hypertension [30]. An option worth 
consideration is individualization of blood pressure 
Table 4 Summary of the expert’s recommendations and its degree of consensus and grade of recommendation
Definitions of degree of consensus and grades of recommendations based on the RAND algorithm. All 34 experts in agreement defined a perfect consensus and 
experts ≥ 80% agreement defined good consensus; both were considered as strong recommendation. Reasonable consensus was defined as 70–80% agreement 
among experts, and the recommendation was considered to be conditional
Statement Degree 
of consensus
Grade 
of recommendation
Blood pressure monitoring
 1. In patients with shock, arterial blood pressure should be monitored invasively and continuously via an 
arterial catheter
Perfect Strong
Ideal moment to start vasopressor therapy in treating circulatory shock
 2. Vasopressors should be started early, before (complete) completion of fluid resuscitation Reasonable Conditional
 3. MAP or the combination of MAP and DAP should be considered as trigger to start vasopressor treat‑
ment
Good Strong
Vasopressor of first choice
 4. Norepinephrine should be used as vasopressor of first choice Perfect Strong
Target of vasopressor treatment
 5. The target of vasopressor therapy should be a MAP of 65 mmHg Good Strong
 6. Lower MAPs are tolerated in case of refractory hypotension despite adequate fluid and vasopressor 
treatment
Good Strong
Treatment options in refractory hypotension
 7. Adding a second vasopressor in case of refractory hypotension Good Strong
 8. Using vasopressin or terlipressin as second vasopressor Good Strong
Reason to stop vasopressor treatment
 9. Vasopressor treatment should be reduced/stopped when the patient improves clinically, when side 
effects occur, or in case of ineffectiveness
Perfect Strong
Use of steroids to reach target
 10. Steroids should be considered in septic shock Good Strong
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targets, based on a “vasopressor challenge,” with return 
to the previous vasopressor dose if organ perfusion does 
not obviously improve while higher MAP levels were 
achieved, or if adverse effects such as atrial fibrillation or 
myocardial ischemia occur. The efficacy of this pragmatic 
strategy has not yet been confirmed by prospective stud-
ies, but has been tested in a recently completed study on 
early resuscitation in septic shock patients [31].
The choice of first-line vasopressor in our survey 
agrees with reports from Scandinavian and Canadian 
ICUs where norepinephrine was the first-line vasopres-
sor used to achieve MAP targets [32, 33]. This is a sig-
nificant change from an earlier survey where dopamine 
was the first-line vasopressor [34]. A large multicenter 
randomized controlled trial comparing norepinephrine 
versus dopamine [6], three meta-analyses [35–37], and 
subsequent guideline recommendations [7, 8] are likely 
to be the main contributors to this shift in practice. A 
recent retrospective analysis reported an increased mor-
tality rate in septic shock patients managed with differ-
ent vasopressors (predominantly phenylephrine) during a 
period of norepinephrine shortage in the USA [38, 39]. 
This implies that norepinephrine may be the vasopressor 
associated with the lowest mortality. Consequently, the 
2016 SSC states that phenylephrine use should be limited 
until more research is available since its impact on clini-
cal outcomes is uncertain [8].
The 2016 Surviving Sepsis Campaign suggests adding 
either vasopressin (up to 0.03  U  min−1) (weak recom-
mendation, moderate quality of evidence) or epineph-
rine (weak recommendation, low quality of evidence) to 
norepinephrine with the intent of raising MAP to target 
or adding vasopressin (up to 0.03 U min−1) (weak recom-
mendation, moderate quality of evidence) to decrease 
norepinephrine dosage [8]. However, recent studies 
found no beneficial outcome effect from vasopressin [40] 
or terlipressin [41]. Angiotensin II has been studied as 
an additional vasopressor to maintain MAP in a recent 
randomized controlled trial in patients with vasodila-
tory shock [42]. Its exact place in the treatment of sep-
tic shock needs to be defined, but a subgroup analysis of 
the latter study suggests that patients with acute kidney 
injury requiring renal replacement may preferentially 
benefit from this treatment [43].
The timing to initiate vasopressor therapy varied in 
our survey; 44% of responders would start vasopres-
sors after assessment of preload dependency, while 
27% would use vasopressors only after complete cor-
rection of hypovolemia as assessed by preload depend-
ency variables. The experts agreed with a conditional 
degree of consensus that vasopressors should be started 
before the completion of full fluid resuscitation. From 
the SSC guidelines, there is uncertainty about when 
vasopressors should be initiated in septic shock. After 
careful reading of the publication, it might be under-
stood that vasopressors should be administered only 
after the initial fluid resuscitation (30 mL kg−1 of crys-
talloids within the first 3 h) [7]. This lack of clarity was 
criticized [44]. Data from the Australasian Resuscita-
tion In Sepsis Evaluation (ARISE) trial showed that 
the median [IQR] volume of fluid administered before 
starting a vasopressor was 3.1 [2.3, 4.3] L [45].
Recently (after completion of our survey), the SSC 
proposed a new 1-hour bundle where vasopressors 
are recommended to be applied if the patient is hypo-
tensive during or after fluid resuscitation to maintain 
MAP ≥ 65  mmHg [9]. Although it is not mentioned 
which indicator can be used to select patients who 
require vasopressors, this recommendation clearly 
indicates that early administration before complete 
fluid resuscitation is an option. Some studies reported 
that delay in initiation of vasopressor therapy was asso-
ciated with an increased mortality risk in patients with 
septic shock [46, 47]. There are three potential reasons 
for this finding: early vasopressors could prevent the 
onset or progression of organ dysfunction by reaching 
the target MAP (as the main component of organ per-
fusion pressure) faster and by optimizing tissue perfu-
sion [48, 49]. Earlier vasopressor therapy may represent 
a marker of the intensity of delivered care which could 
result in improved outcome. Finally, earlier vasopres-
sor use could lead to a decrease in the amount of fluids 
administered [50], e.g., due to a redistribution of venous 
blood from unstressed to stressed volume (autotransfu-
sion). However, retrospective data from almost 2900 
patients from 24 hospitals in three countries suggest 
that starting vasoactive agents in the initial hour may 
be detrimental due to less fluids being given and that 
mortality was lowest when vasoactive agents were initi-
ated 1–6 h after septic shock onset, with more than 1 L 
of fluids in the initial hour, more than 2.4 L from hours 
1–6, and 1.6–3.5  L from 6 to 24  h [51]. In the ARISE 
trial, 50% of the patients received vasopressors within 
4.4 h after hospital admission [45]. As these data reflect 
epidemiology rather than physiology, the optimal tim-
ing of vasopressor initiation needs to be studied in a 
personalized context.
In our survey, there was a discrepancy in the respond-
ents’ opinion as to reasons why a second vasopressor 
should be added in patients with refractory hypotension, 
i.e., when a patient does not adequately respond to the 
initial vasopressor treatment. Only 14% of respondents 
cited a predefined maximum dose of the first vasopres-
sor as the main reason. There is some support for this in 
the current literature as a post hoc analysis study found 
that vasopressor load and thresholds of dose have been 
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related to mortality in septic shock [52]. This might be 
related to the occurrence of catecholamine-associated 
complications although the mortality associated with 
high-dose norepinephrine varies considerably. In a 
series of 324 patients with septic shock (average mor-
tality rate 48%), patients who received norepinephrine 
doses ≥ 1  µg  kg−1  min−1 had an extremely high (90%) 
mortality rate [53]. By contrast, in a series of 106 patients 
with severe septic shock who received ≥ 1 µg kg−1 min−1, 
the mortality rate was far lower (60%) [35]. Research is 
needed to identify clinically relevant thresholds for the 
consistency of guidelines and for design of future clinical 
trials [54].
Regarding the use of corticosteroids in refractory hypo-
tension, 29/34 experts recommended its use despite 
the lack of strong evidence showing mortality benefit 
[55–57]. However, there is evidence that use of low-
dose corticosteroids results in earlier shock reversal (i.e., 
reduced duration of vasopressor therapy with stable 
hemodynamics) in patients with septic shock unrespon-
sive to fluid and vasopressor therapy [56–58]. Of note, 
no expert changed his/her mind after the results of the 
ADRENAL trial [21] became available, whereas two of 
the five experts with an initially negative attitude changed 
their opinion in favor of steroids after the results of the 
APROCCHSS trial [22].
In our survey, we received contradictory responses 
to the question regarding the change in cardiac output 
when restoring MAP with norepinephrine. Only 53% 
of physicians acknowledged that using norepinephrine 
to improve MAP might also result in an increase in sys-
temic blood flow. Studies have shown increases in car-
diac output through an increase in cardiac preload and 
cardiac contractility in patients with septic shock treated 
with norepinephrine [48, 59–62]. A recent system-
atic review has confirmed these findings [63]. Although 
24% of responding physicians considered that restoring 
MAP with norepinephrine might result in a reduction 
in microcirculatory blood flow, this is not supported by 
recent studies showing improvements [49, 61, 64, 65], or 
no change [66–68] in microvascular perfusion in patients 
with septic shock when blood pressure was increased 
with norepinephrine. It appears that the effect of nor-
epinephrine was dependent on the basal microvascular 
state, being beneficial only when the microcirculation 
was compromised.
Respondents had different opinions on how to meas-
ure blood pressure, MAP targets, dosing, timing, triggers 
for adding a second vasopressor, reasons for reducing the 
vasopressor dose, and stopping vasopressor treatment. 
This variation may be interpreted in two ways. Firstly, 
individual physicians may interpret the existing scientific 
evidence differently. For example, one physician may give 
more weight to a MAP target, while another may focus 
on signs of organ dysfunction. This is supported by the 
finding that 68% of respondents preferred MAP and 
21% organ function markers as their target for vasopres-
sor therapy. Secondly, the physicians may have inter-
preted the existing evidence in a similar manner, while 
the heterogeneity of septic shock drives the differences 
in treatment plans. These treatments may be adapted 
to individual patients based on their history, underly-
ing disease, comorbidities, and response to treatment 
[69]. In clinical practice, a MAP target of 65 mmHg may 
be acceptable provided no other signs of hypoperfusion 
are present. If signs of hypoperfusion remain, the MAP 
target may need to be elevated. These nuances cannot be 
captured by a simple survey.
Although surveys are not at the top of the evidence-
based pyramid, the results of this survey present useful 
information on contemporary practice and preferences 
regarding vasopressor therapy, obtained from respond-
ers from many European and non-European countries 
(Fig. 2). Non-European physicians more often used non-
invasive techniques to measure ABP and less frequently 
considered other reasons than reaching the MAP target 
to increase the vasopressor dosage, such as persisting 
signs of organ dysfunction despite reaching MAP targets. 
These differences might reflect varying adoption rates of 
the Surviving Sepsis Campaign guidelines, or simply dif-
ferences in available resources and local practices.
The experts’ opinions are based on the available evi-
dence and their interpretation thereof for most of the 
questions, while its added value may especially lie in the 
questions where evidence is sparse. Furthermore, this 
work identified areas for future research as reflected by 
heterogeneous opinions.
The results of our survey can be used as a benchmark 
for interpreting studies stating usual or standard care 
in control groups of intervention trials. However, if the 
control group is treated (very) differently from what was 
reported in our survey, then external validity of results is 
diminished. Physicians are less swayed by the impact of 
an intervention when compared against a control inter-
vention that is currently not considered as standard 
for treating patients. Furthermore, future trials can be 
designed to investigate changes against what is consid-
ered usual or standard care to increase the external valid-
ity. Another positive aspect of this survey is that it can be 
used to guide education, for example the need to avoid 
unnecessary fluid overload.
Limitations
The methods used to invite individuals to respond to our 
survey did not allow us to calculate the exact response 
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rate, which can be estimated to around 10% of all ESICM 
members. Nevertheless, our survey had by far the larg-
est absolute number of respondents as compared to 
previous surveys on vasopressors (839 vs. 114, 171, and 
202, respectively) [32–34]. Still, a response bias can-
not be excluded. Results relate only to individuals who 
were willing to respond. External validity is therefore 
hampered. In addition, online surveys have limitations, 
including multiple responses by a single person. We did 
not use cookies or log-file/IP address analyses to pre-
vent multiple responses. On the other hand, we assume 
that single persons are unlikely to spend time answering 
a simple survey more than once, and we are not aware 
if some institutions had higher representations among 
respondents than others. Furthermore, a survey may not 
reflect bedside practice rather than preferences, even in 
the institutions of the physicians answering the survey. 
In addition, questions and definitions used in our survey 
might have been interpreted differently by the respond-
ents hampering their answers. Similarly, it should be 
noted that we currently have the third international con-
sensus definition of sepsis [15], whereas most of the stud-
ies cited in the discussion were based on the criteria of 
the second definition.
Conclusion
In conclusion, vasopressor use in critically ill patients 
with septic shock, as self-reported by individual physi-
cians, is compliant with current guidelines. Experts rec-
ommended not to delay vasopressor treatment until fluid 
resuscitation is completed, but rather to start with norep-
inephrine early to achieve a target MAP of ≥ 65 mmHg. 
Future studies should focus on the implementation of 
current evidence on the early use of vasopressors, indi-
vidualized hemodynamic targets, and patient outcomes 
[54]. A logical follow-up would be a systematic review on 
the use of vasopressors in critically ill adult patients with 
circulatory shock.
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